2022 Mpox (Monkeypox) Outbreak:
Global Trends

World Health Organization

Produced on 10 January 2023

logo

Key Figures

1 Overview

This report provides a global overview of the mpox1 epidemiological situation as reported to WHO as of January 09 2023. The report focuses on laboratory confirmed cases2 as defined by the WHO’s working case definition published in the Surveillance, case investigation and contact tracing for monkeypox interim guidance. Note that countries may use their own case definitions separate from those outlined in the above document. This report should be considered in the context of other WHO information products associated with the 2022 mpox outbreak, and mpox in general:

  • The biweekly Situation Report provides a comprehensive update of the mpox situation and response activities across a variety of domains such as epidemiology, clinical management and communications, replacing the previous Disease Outbreak News format;

  • This global epidemiological report provides in-depth epidemiological information about the mpox situation, based primarily on case report forms provided by Member States to WHO under Article 6 of the International Health Regulations (IHR 2005).

Links to these products can be see in more detail at the end of the report.

Since 1 January 2022, cases of mpox have been reported to WHO from 110 Member States across all 6 WHO regions. As of January 09 2023 at 17h CET, a total of 84,415 laboratory confirmed cases and 1,348 probable cases, including 76 deaths, have been reported to WHO. Since 13 May 2022, a high proportion of these cases have been reported from countries without previously documented mpox transmission. This is the first time that cases and sustained chains of transmission have been reported in countries without direct or immediate epidemiological links to areas of West or Central Africa.

With the exception of countries3,4 in West and Central Africa, the ongoing outbreak of mpox continues to primarily affect men who have sex with men. At present there is no signal suggesting sustained transmission beyond these networks.

Confirmation of one case of mpox, in a country, is considered an outbreak. The unexpected appearance of mpox in several regions in the initial absence of epidemiological links to areas in West and Central Africa, suggests that there may have been undetected transmission for some time.

WHO assesses the global risk as Moderate. Regionally, WHO assesses the risk in the Region of the Americas as High and as Moderate in the African Region, Eastern Mediterranean Region, European Region and the South-East Asia Region. The risk in the Western Pacific Region is assessed as Low. The IHR Emergency Committee on the multi-country outbreak of mpox held its third meeting on 20 October 2022. Having considered the views of committee members and advisors as well as other factors in line with the International Health Regulations (2005), the WHO Director-General determined that this outbreak continues to constitute a public health emergency of international concern and issued revised temporary recommendations in relation to the outbreak.

 


  1. On of 28 November 2022, WHO recommended using the name mpox as a new name for monkeypox. The words will be used synonymously for one year while the term monkeypox is phased out.

  2. For the WHO European region, both confirmed and probable cases are included within confirmed case counts and detailed case data.

  3. Throughout this document, any use of the word country should be considered shorthand for a country, area, or territory

  4. All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).


2 Global situation update

The number of weekly1 reported new cases globally has decreased by 36.3% in week 1 (02 Jan - 08 Jan) (n = 330 cases) compared to week 52 (26 Dec - 01 Jan) (n = 518 cases). The majority of cases reported in the past 4 weeks were notified from the Region of the Americas (82.2%) and the African Region (9.4%).

The 10 most affected countries globally are: United States of America (n = 29,724), Brazil (n = 10,573), Spain (n = 7,500), France (n = 4,114), Colombia (n = 4,035), The United Kingdom (n = 3,730), Peru (n = 3,683), Germany (n = 3,677), Mexico (n = 3,637), and Canada (n = 1,460). Together, these countries account for 85.5% of the cases reported globally.

In the past 7 days, 17 countries reported an increase in the weekly number of cases, with the highest increase reported in United States of America. 77 countries have reported no new cases in the past 21 days.

Global data are data collected by public sources. These data are largely aggregated cases that have been reported from open and official country sources. The below epidemic curve shows the aggregated number of cases by week according to the date of case reporting.

2.1 Epidemic curves

2.1.1 Global (cases)

Epidemic curve shown for cases reported up to 08 Jan 2023 to avoid showing incomplete weeks of data.

2.1.2 Global (deaths)

Epidemic curve shown for deaths reported up to 08 Jan 2023 to avoid showing incomplete weeks of data.

2.1.3 By WHO Region (cases)

Epidemic curve shown for cases reported up to 08 Jan 2023 to avoid showing incomplete weeks of data. Note different y-axis scales.

2.1.4 By WHO Region (deaths)

Epidemic curve shown for deaths reported up to 08 Jan 2023 to avoid showing incomplete weeks of data. Note different y-axis scales.

2.1.5 Top 10 countries (cases)

Epidemic curve shown for cases reported up to 08 Jan 2023 to avoid showing incomplete weeks of data. Note different y-axis scales.

2.1.6 Epidemic curve by country

Epidemic curve shown for cases reported up to 09 Jan 2023 to avoid showing incomplete weeks of data. In general, trends should be interpretted with caution, as the majority of countries do not report cases on a daily basis.

2.2 Maps

Note: Maps can be clicked to view on a larger scale

2.2.1 Cumulative cases

2.2.2 Weekly cases

2.2.3 Weekly change in cases

2.3 Tables

2.3.1 Cumulative Cases and deaths by WHO Region

Total mpox cases, by WHO region
From 1 Jan 2022. Data as of 09 Jan 2023
Total Confirmed Cases Total Probable Cases Total Deaths Cases in the last week1 Cases in the preceding week Weekly % change in cases1
Region of the Americas 57,133 1,348 54 294 510 −42%
European Region 25,738 0 5 33 6 450%
African Region 1,200 0 15 3 2 50%
Western Pacific Region 229 0 0 0 0 –
Eastern Mediterranean Region 80 0 1 0 0 –
South-East Asia Region 35 0 1 0 0 –
Total 84,415 1,348 76 330 518 −36%
1 Using most recently complete international standard week (Monday - Sunday)


2.3.2 Cumulative cases and deaths by country

Total Mpox cases, by WHO region
From 1 Jan 2022. Data as of 09 Jan 2023
Total Confirmed Cases Total Probable Cases Total Deaths
Region of the Americas
United States of America 29,724 0 21
Brazil 10,573 689 14
Colombia 4,035 0 0
Peru 3,683 0 8
Mexico 3,637 402 4
Canada 1,460 78 0
Chile 1,387 23 2
Argentina 1,025 0 2
Ecuador 441 1 2
Guatemala 277 4 0
Bolivia (Plurinational State of) 262 0 0
Puerto Rico 209 150 0
Panama 82 0 0
Costa Rica 77 0 0
El Salvador 69 0 0
Paraguay 56 0 0
Dominican Republic 52 1 0
Uruguay 19 0 0
Jamaica 18 0 0
Venezuela (Bolivarian Republic of) 12 0 0
Honduras 12 0 0
Cuba 8 0 1
Aruba 3 0 0
Curaçao 3 0 0
Bahamas 2 0 0
Guyana 2 0 0
Barbados 1 0 0
Bermuda 1 0 0
Saint Martin 1 0 0
Guadeloupe 1 0 0
Martinique 1 0 0
European Region
Spain 7,500 0 3
France 4,114 0 0
The United Kingdom 3,730 0 0
Germany 3,677 0 0
Netherlands 1,259 0 0
Italy 951 0 0
Portugal 950 0 0
Belgium 790 0 1
Switzerland 551 0 0
Austria 327 0 0
Israel 262 0 0
Sweden 255 0 0
Ireland 227 0 0
Poland 214 0 0
Denmark 192 0 0
Norway 94 0 0
Greece 85 0 0
Hungary 80 0 0
Czechia 71 0 1
Luxembourg 57 0 0
Slovenia 47 0 0
Romania 46 0 0
Finland 42 0 0
Serbia 40 0 0
Malta 33 0 0
Croatia 31 0 0
Iceland 16 0 0
Slovakia 14 0 0
Türkiye 12 0 0
Estonia 11 0 0
Bosnia and Herzegovina 9 0 0
Bulgaria 6 0 0
Gibraltar 6 0 0
Latvia 6 0 0
Cyprus 5 0 0
Lithuania 5 0 0
Ukraine 5 0 0
Andorra 4 0 0
Monaco 3 0 0
Georgia 2 0 0
Greenland 2 0 0
Republic of Moldova 2 0 0
Montenegro 2 0 0
Russian Federation 2 0 0
San Marino 1 0 0
African Region
Nigeria 756 0 7
Democratic Republic of the Congo 277 0 0
Ghana 116 0 4
Cameroon 18 0 3
Central African Republic 13 0 0
Liberia 6 0 0
Congo 5 0 0
South Africa 5 0 0
Benin 3 0 0
Mozambique 1 0 1
Western Pacific Region
Australia 144 0 0
New Zealand 40 0 0
Singapore 19 0 0
Japan 8 0 0
China1 6 0 0
Philippines 4 0 0
Republic of Korea 4 0 0
Viet Nam 2 0 0
New Caledonia 1 0 0
Guam 1 0 0
Eastern Mediterranean Region
Lebanon 24 0 0
Sudan 18 0 1
United Arab Emirates 16 0 0
Saudi Arabia 8 0 0
Qatar 5 0 0
Morocco 3 0 0
Egypt 3 0 0
Iran (Islamic Republic of) 1 0 0
Jordan 1 0 0
Bahrain 1 0 0
South-East Asia Region
India 20 0 1
Thailand 12 0 0
Sri Lanka 2 0 0
Indonesia 1 0 0
-
Total 84,415 1,348 76
1 Cases shown include those in mainland China (1), Hong Kong SAR (1) and Taipei (4)


2.3.3 Weekly changes - African Region

Summary of Mpox cases
As of 09 Jan 2023
Total Cases Total cases per 1M inhabitants Cases in the last week1 Cases in the preceding week Weekly % change in cases1 Days since last report Date of first reported case
African Region
Nigeria 756 4 3 0 – 0 02 Jan 2022
Democratic Republic of the Congo 277 3 0 0 – 0 13 Jun 2022
Ghana 116 4 0 0 – 0 13 Jun 2022
Cameroon 18 1 0 0 – 0 13 Jun 2022
Central African Republic 13 3 0 0 – 0 13 Feb 2022
Liberia 6 1 0 2 – 0 01 Aug 2022
Congo 5 1 0 0 – 0 21 May 2022
South Africa 5 0 0 0 – 0 23 Jun 2022
Benin 3 0 0 0 – 0 15 Jun 2022
Mozambique 1 0 0 0 – 0 14 Sep 2022
1 Using most recently complete international standard week (Monday - Sunday)


2.3.4 Weekly changes - Region of the Americas

Summary of Mpox cases
As of 09 Jan 2023
Total Cases Total cases per 1M inhabitants Cases in the last week1 Cases in the preceding week Weekly % change in cases1 Days since last report Date of first reported case
Region of the Americas
United States of America 29,724 90 121 49 150% 2 03 Jun 2022
Brazil 10,573 50 62 63 −2% 2 10 Jun 2022
Colombia 4,035 79 14 50 −72% 2 25 Jun 2022
Peru 3,683 112 40 14 190% 2 28 Jun 2022
Mexico 3,637 28 0 128 – 2 03 Jun 2022
Canada 1,460 39 0 0 – 2 03 Jun 2022
Chile 1,387 73 10 5 100% 2 18 Jun 2022
Argentina 1,025 23 7 31 −77% 2 03 Jun 2022
Ecuador 441 25 0 95 – 2 06 Jul 2022
Guatemala 277 16 18 15 20% 2 04 Aug 2022
Bolivia (Plurinational State of) 262 22 1 0 – 2 03 Aug 2022
Puerto Rico 209 73 1 1 0% 2 01 Jul 2022
Panama 82 19 4 0 – 2 06 Jul 2022
Costa Rica 77 15 7 33 −79% 2 21 Jul 2022
El Salvador 69 11 0 17 – 2 01 Sep 2022
Paraguay 56 8 8 9 −11% 2 26 Aug 2022
Dominican Republic 52 5 0 0 – 2 07 Jul 2022
Uruguay 19 6 0 0 – 2 31 Jul 2022
Jamaica 18 6 0 0 – 2 08 Jul 2022
Honduras 12 1 1 0 – 2 14 Aug 2022
Venezuela (Bolivarian Republic of) 12 0 0 0 – 2 15 Jun 2022
Cuba 8 1 0 0 – 2 23 Aug 2022
Aruba 3 28 0 0 – 2 24 Aug 2022
Curaçao 3 18 0 0 – 2 20 Aug 2022
Bahamas 2 5 0 0 – 2 27 Jun 2022
Guyana 2 2 0 0 – 2 24 Aug 2022
Barbados 1 4 0 0 – 2 19 Jul 2022
Bermuda 1 16 0 0 – 2 23 Jul 2022
Guadeloupe 1 2 0 0 – 2 05 Aug 2022
Martinique 1 3 0 0 – 2 20 Jul 2022
Saint Martin 1 26 0 0 – 2 04 Aug 2022
1 Using most recently complete international standard week (Monday - Sunday)


2.3.5 Weekly changes - Eastern Mediterranean Region

Summary of Mpox cases
As of 09 Jan 2023
Total Cases Total cases per 1M inhabitants Cases in the last week1 Cases in the preceding week Weekly % change in cases1 Days since last report Date of first reported case
Eastern Mediterranean Region
Lebanon 24 4 0 0 – 44 20 Jun 2022
Sudan 18 0 0 0 – 82 01 Aug 2022
United Arab Emirates 16 2 0 0 – 169 24 May 2022
Saudi Arabia 8 0 0 0 – 132 14 Jul 2022
Qatar 5 2 0 0 – 111 21 Jul 2022
Egypt 3 0 0 0 – 28 27 Sep 2022
Morocco 3 0 0 0 – 133 02 Jun 2022
Bahrain 1 1 0 0 – 115 16 Sep 2022
Iran (Islamic Republic of) 1 0 0 0 – 144 18 Aug 2022
Jordan 1 0 0 0 – 123 08 Sep 2022
1 Using most recently complete international standard week (Monday - Sunday)


2.3.6 Weekly changes - Table - European Region

Summary of Mpox cases
As of 09 Jan 2023
Total Cases Total cases per 1M inhabitants Cases in the last week1 Cases in the preceding week Weekly % change in cases1 Days since last report Date of first reported case
European Region
Spain 7,500 158 4 0 – 3 18 May 2022
France 4,114 63 0 4 – 3 19 May 2022
The United Kingdom 3,730 55 0 0 – 3 07 May 2022
Germany 3,677 44 1 0 – 3 20 May 2022
Netherlands 1,259 72 3 0 – 3 22 May 2022
Italy 951 16 13 2 550% 3 19 May 2022
Portugal 950 92 2 0 – 3 17 May 2022
Belgium 790 69 0 0 – 3 19 May 2022
Switzerland 551 64 0 0 – 3 21 May 2022
Austria 327 37 0 0 – 3 23 May 2022
Israel 262 30 0 0 – 3 21 May 2022
Sweden 255 25 5 0 – 3 18 May 2022
Ireland 227 46 2 0 – 3 16 May 2022
Poland 214 6 0 0 – 3 13 Jun 2022
Denmark 192 33 0 0 – 3 23 May 2022
Norway 94 18 1 0 – 3 31 May 2022
Greece 85 8 0 0 – 3 09 Jun 2022
Hungary 80 8 0 0 – 3 31 May 2022
Czechia 71 7 0 0 – 3 24 May 2022
Luxembourg 57 91 0 0 – 3 16 Jun 2022
Slovenia 47 22 0 0 – 3 24 May 2022
Romania 46 2 0 0 – 3 14 Jun 2022
Finland 42 8 0 0 – 3 20 May 2022
Serbia 40 6 0 0 – 3 17 Jun 2022
Malta 33 64 0 0 – 3 30 May 2022
Croatia 31 8 2 0 – 3 24 Jun 2022
Iceland 16 44 0 0 – 3 09 Jun 2022
Slovakia 14 3 0 0 – 3 07 Jul 2022
Türkiye 12 0 0 0 – 3 30 Jun 2022
Estonia 11 8 0 0 – 3 28 Jun 2022
Bosnia and Herzegovina 9 3 0 0 – 3 14 Jul 2022
Bulgaria 6 1 0 0 – 3 23 Jun 2022
Gibraltar 6 178 0 0 – 3 02 Jun 2022
Latvia 6 3 0 0 – 3 03 Jun 2022
Cyprus 5 6 0 0 – 3 03 Aug 2022
Lithuania 5 2 0 0 – 3 04 Aug 2022
Ukraine 5 0 0 0 – 3 15 Sep 2022
Andorra 4 52 0 0 – 3 25 Jul 2022
Monaco 3 76 0 0 – 3 12 Aug 2022
Georgia 2 0 0 0 – 3 15 Jun 2022
Greenland 2 35 0 0 – 3 10 Aug 2022
Montenegro 2 3 0 0 – 3 31 Jul 2022
Republic of Moldova 2 0 0 0 – 3 09 Aug 2022
Russian Federation 2 0 0 0 – 3 12 Jul 2022
San Marino 1 30 0 0 – 3 29 Sep 2022
1 Using most recently complete international standard week (Monday - Sunday)


2.3.7 Weekly changes - South-East Asia Region

Summary of Mpox cases
As of 09 Jan 2023
Total Cases Total cases per 1M inhabitants Cases in the last week1 Cases in the preceding week Weekly % change in cases1 Days since last report Date of first reported case
South-East Asia Region
India 20 0 0 0 – 28 14 Jul 2022
Thailand 12 0 0 0 – 28 21 Jul 2022
Sri Lanka 2 0 0 0 – 28 04 Nov 2022
Indonesia 1 0 0 0 – 28 22 Aug 2022
1 Using most recently complete international standard week (Monday - Sunday)


2.3.8 Weekly changes - Western Pacific Region

Summary of Mpox cases
As of 09 Jan 2023
Total Cases Total cases per 1M inhabitants Cases in the last week1 Cases in the preceding week Weekly % change in cases1 Days since last report Date of first reported case
Western Pacific Region
Australia 144 6 0 0 – 31 20 May 2022
New Zealand 40 8 0 0 – 31 11 Jul 2022
Singapore 19 3 0 0 – 116 21 Jun 2022
Japan 8 0 0 0 – 17 25 Jul 2022
China2 6 0 0 0 – 92 24 Jun 2022
Philippines 4 0 0 0 – 140 29 Jul 2022
Republic of Korea 4 0 0 0 – 47 22 Jun 2022
Viet Nam 2 0 0 0 – 82 03 Oct 2022
Guam 1 6 0 0 – 119 12 Sep 2022
New Caledonia 1 4 0 0 – 181 12 Jul 2022
1 Using most recently complete international standard week (Monday - Sunday)
2 Cases shown include those in mainland China (1), Hong Kong SAR (1) and Taipei (4)


2.3.9 Countries with last case reported 21 or more days ago

Days since last reported case
As of 09 Jan 2023
Last Reported Case Days Elapsed
African Region
Benin 15 Jun 2022 208
South Africa 29 Aug 2022 133
Congo 15 Sep 2022 116
Mozambique 11 Oct 2022 90
Cameroon 19 Dec 2022 21
Central African Republic 19 Dec 2022 21
Ghana 19 Dec 2022 21
Western Pacific Region
New Caledonia 12 Jul 2022 181
Philippines 22 Aug 2022 140
Guam 12 Sep 2022 119
Singapore 15 Sep 2022 116
China 9 Oct 2022 92
Viet Nam 19 Oct 2022 82
Republic of Korea 23 Nov 2022 47
Australia 9 Dec 2022 31
New Zealand 9 Dec 2022 31
Region of the Americas
Barbados 19 Jul 2022 174
Martinique 20 Jul 2022 173
Bermuda 23 Jul 2022 170
Saint Martin 4 Aug 2022 158
Guadeloupe 5 Aug 2022 157
Bahamas 20 Aug 2022 142
Guyana 30 Aug 2022 132
Aruba 13 Sep 2022 118
Curaçao 22 Sep 2022 109
Dominican Republic 7 Oct 2022 94
Cuba 9 Nov 2022 61
Jamaica 25 Nov 2022 45
Eastern Mediterranean Region
United Arab Emirates 24 Jul 2022 169
Iran (Islamic Republic of) 18 Aug 2022 144
Morocco 29 Aug 2022 133
Saudi Arabia 30 Aug 2022 132
Jordan 8 Sep 2022 123
Bahrain 16 Sep 2022 115
Qatar 20 Sep 2022 111
Sudan 19 Oct 2022 82
Lebanon 26 Nov 2022 44
Egypt 12 Dec 2022 28
European Region
Andorra 5 Aug 2022 157
Greenland 10 Aug 2022 152
Gibraltar 11 Aug 2022 151
Lithuania 11 Aug 2022 151
Monaco 12 Aug 2022 150
Georgia 17 Aug 2022 145
Republic of Moldova 17 Aug 2022 145
Montenegro 22 Aug 2022 140
Cyprus 29 Aug 2022 133
Slovakia 4 Sep 2022 127
Malta 6 Sep 2022 125
Russian Federation 11 Sep 2022 120
Bulgaria 13 Sep 2022 118
Estonia 13 Sep 2022 118
Serbia 21 Sep 2022 110
Slovenia 26 Sep 2022 105
Iceland 5 Oct 2022 96
Latvia 5 Oct 2022 96
Türkiye 5 Oct 2022 96
San Marino 10 Oct 2022 91
Ukraine 10 Oct 2022 91
Bosnia and Herzegovina 12 Oct 2022 89
Hungary 25 Oct 2022 76
Israel 31 Oct 2022 70
Finland 4 Nov 2022 66
Greece 13 Nov 2022 57
Luxembourg 15 Nov 2022 55
Poland 29 Nov 2022 41
Austria 2 Dec 2022 38
Czechia 2 Dec 2022 38
Belgium 6 Dec 2022 34
Romania 6 Dec 2022 34
Switzerland 6 Dec 2022 34
The United Kingdom 6 Dec 2022 34
Denmark 13 Dec 2022 27
South-East Asia Region
Indonesia 22 Aug 2022 140
Thailand 24 Oct 2022 77
Sri Lanka 15 Nov 2022 55
India 12 Dec 2022 28


 



  1. Weekly reported cases, and weekly cases shown in the epidemic curve are aggregated according to international standard weeks, running from Monday to Sunday.

3 Detailed case data

Detailed case data are acquired via direct reporting of case based data via WHO Member States. Data from cases are reported1 according to the WHO minimum dataset under the International Health Regulations (IHR 2005) Article 6, and subsequently aggreagated and presented below. Note that completeness of records is variable, meaning denominators for each output may be different from one another. All of the following is derived from the detailed case data, and as a result, overall numbers may not be reflective of figures shown with aggregate case numbers. All detailed cases shown are confirmed cases, where the reporting date occured after 01 January 2022.


  1. Note that a small number of detailed case reports are constructed from official public reports about individual cases.

3.1 Reporting coverage

The detailed case dataset was last updated on January 06 2023. As of this date, the total number of detailed confirmed cases reported is 80,363, representing 95.2% of all aggregated cases reported.

The table below indicates the reporting coverage between reported aggregated confirmed cases and detailed confirmed cases by countries and per region.

Note that for all tables below, in order to best align modes of reporting, total confirmed cases are shown as of:

  1. The most recent Friday (06 January) for data in the Region of the Americas.

  2. The most recent Tuesday (03 January) for data in the European Region.

Total cases shown fully as of 09 January are shown in the global trends section.

3.1.1 Table - Coverage by region

Mpox reporting completeness
As of 09 Jan 20231
Total Confirmed Cases Total Detailed Confirmed Cases2 % Detailed Cases reported
Region of the Americas 57,110 54,329 95.1%
European Region 25,736 25,656 99.7%
African Region 1,200 174 14.5%
Western Pacific Region 229 114 49.8%
Eastern Mediterranean Region 80 55 68.8%
South-East Asia Region 35 35 100.0%
1 Total confirmed cases shown as of date of last detailed case report for the WHO Region of the Americas and WHO European Region.
2 Note that in rare cases total detailed cases may exceed total confirmed cases due to ongoing data cleaning issues




3.3 Case profile (overall)

As shown below, and stated previously, the ongoing outbreak is largely developing in men who have sex with men (defined as homosexual or bisexual males in detailed case forms) networks. In the following analyses, we have re-coded men reported as bisexual as men who have sex with men. Note that reported sexual orientation does not necessarily reflect who the case has had recent sexual history with nor does it imply sexual activity. Generally, severity has been low, with few reported hospitalisations and deaths:

Key features of these cases are as follows:

  • 96.6% (72122/74663) of cases with available data are male, the median age is 34 years (IQR: 29 - 41).

  • Males between 18-44 years old continue to be disproportionately affected by this outbreak as they account for 79.2% of cases.

  • Of all cases with available data, 3.4% (2541/74663) are female:

    • The majority of of these cases are reported from the Region of the Americas (2025/2541; 80%) and the European Region (434/2541; 17%)

    • Of the cases where sexual orientation is reported, the majority are Heterosexual (880/995; 88%).

    • The most commonly reported exposure setting is in a household (42/95; 44%), and the most common form of transmission is via sexual encounters (225/557; 40%)

  • Of the 80,159 cases where age was available, there were 795 (1.0%) cases reported aged 0-17, out of which 212 (0.3%) were aged 0-4:

    • The majority of cases aged 0-17 are reported from the Region of the Americas (642 /795; 81%).

    • Of the cases aged 0-17, 0 have reported exposure in a school setting.

  • 55 female cases were reported to be pregnant or recently pregnant. Of these:

    • 4, 11, and 9 cases were in their first, second, and third trimesters respectively. 30 were in an unknown trimester, and 1 were six weeks or less post partum.

    • The median age was 28 years old (IQR: 23 - 31).

    • 12 of these cases were known to be hospitalised. 0 were known to be admitted to ICU, and hospitalised. 0 were known to have died.

    • The most common mode of transmission was other (4/7 cases where route was known). The most common exposure setting was household (2/2 cases where setting was known).

  • Among cases with known data on sexual orientation, 84.3% (26160/31025) identified as men who have sex with men. Of those identified as men who have sex with men, 1702/26160 (6.5%) were identified as bisexual men.

  • Among those with known HIV status 48.2% (16,684/34,649) were HIV-positive. Note that information on HIV status is not available for the majority of cases, and for those for which it is available, it is likely to be skewed towards those reporting positive HIV results.

  • 1193 cases were reported to be health workers. However, most were infected in the community and further investigation is ongoing to determine whether the remaining infection was due to occupational exposure.

  • Of all reported types of transmission, a sexual encounter was reported most commonly, with 14,751 of 21,349 (69.1%) of all reported transmission events.

  • Of all settings in which cases were likely exposed, the most common was in party setting with sexual contacts, with 3,395 of 5,067 (67.0%) of all likely exposure categories.

3.3.1 Demographic Information

Note that the proportions shown below should be interpreted with caution. When considering some variables, it is more likely that a yes response will be obtained when compared to a no response after consideration of true proportions of these factors. This is most likely to be true for variables where reported answers can only be yes or no, such as HIV status, health worker status, travel history, hospitalisation, ICU, and death.

Case profiles
As of January 06 2023
Reported values1 Unknown or Missing Value
Yes No
Men who have sex with men 26160 (84.3%) 4865 (15.7%) 49321
HIV-Positive 16676 (48.1%) 17963 (51.9%) 45707
Health worker 1193 (4.3%) 26451 (95.7%) 52702
Travel History 2322 (14.3%) 13937 (85.7%) 64087
Sexual Transmission 14746 (69.1%) 6598 (30.9%) 59002
Hospitalised2 3859 (7.3%) 49205 (92.7%) 27282
ICU 43 (0.3%) 15942 (99.7%) 64361
Died 28 (0.1%) 52470 (99.9%) 27848
1 Note given true proportions of variables, yes reporting may be common than no reporting
2 May be hospitalised for isolation or medical treatment




3.3.2 Age-sex pyramid



3.3.3 Age-sex pyramid by region

Note that only regions with 50 or more cases with age and sex information are shown. Note different x-axis scales.



3.3.4 Age-sex pyramid (Hospitalised cases)

Note that some cases represented below may be hospitalised for isolation rather than treatment purposes.



3.3.5 Age-sex pyramid (ICU cases)

Note that some cases represented below may be hospitalised for isolation rather than treatment purposes.



3.3.6 Sexual orientation by region



3.3.7 Transmission type

Transmission data were available for 21,349/80,363 (26.6%) of cases.

Note that transmission can occur during sex via skin-to-skin contact as well as via bodily fluids. While skin-to-skin contact with lesions remains an important transmission route, mpox virus has been isolated from semen samples and rectal swabs from confirmed cases. Note that person to person contact does not include known sexual, healthcare-associated, and mother to child transmission.



3.3.8 Exposure settings

Exposure setting data were available for 5,885/80,363 (7.3%) of cases.

Note that multiple exposure settings can be attributed to a single case. Here, differentiation between party settings and large events is determined by size of the event, although there is no formal size threshold to distinguish the two.



3.4 Case profile (excluding men who have sex with men)

The following outputs apply to cases that are not men who have sex with men, and sexual orientation is known. Other categories of sexual orientation that are reportable are:

  • Heterosexual
  • Lesbian (women who have sex with women)
  • Other

As stated above, men who have sex with men in this case refers to those who have a reported sexual orientation of men who have sex with men, and men reported as bisexual. As above, note that reported sexual orientation does not necessarily reflect persons who the case has had recent sexual history with nor does it imply sexual activity. Up until this point in time, the 2022 multi-country mpox outbreak has been overwhelmingly concentrated in networks of men who have sex with men For this reason, understanding events in which individuals of other sexual orientation have acquired mpox is important to monitor potential of sustained spillover into the general population.

  • 79.8% (3858/4837) of cases with available data are male; the median age is 33 years (IQR: 26-40).

  • Males between 18-44 years old account for 65.2% of cases.

  • Among those with known HIV status 29.0% (1071/3699) were HIV-positive. Note that information on HIV status is not available for the majority of cases, and for those for which it is available, it is likely to be skewed towards those reporting positive HIV results.

  • 141 cases were reported to be health workers. However, most were infected in the community and further investigation is ongoing to determine whether the remaining infection was due to occupational exposure.

  • Of all reported types of transmission, other was reported most commonly, with 782 of 1,660 (47.1%) of all reported transmission events.

  • Of all settings in which cases were likely exposed, the most common was in party setting with sexual contacts, with 83 of 228 (36.4%) of all likely exposure categories.

3.4.1 Demographic Information

Note that the proportions shown below should be interpreted with caution. When considering some variables, it is more likely that a yes response will be obtained when compared to a no response after consideration of true proportions of these factors. This is most likely to be true for variables where reported answers can only be yes or no, such as HIV status, health worker status, travel history, hospitalisation, ICU, and death.

Case profiles (excluding men who have sex with men)
As of January 06 2023
Reported values1 Unknown or Missing Value
Yes No
Men who have sex with men 0 4865 (100.0%) 0
HIV-Positive 1071 (29.0%) 2628 (71.0%) 1166
Health worker 141 (8.1%) 1596 (91.9%) 3128
Travel History 239 (9.9%) 2175 (90.1%) 2451
Sexual Transmission 561 (33.8%) 1099 (66.2%) 3205
Hospitalised2 391 (10.6%) 3289 (89.4%) 1185
ICU 13 (0.9%) 1480 (99.1%) 3372
Died 4 (0.1%) 3432 (99.9%) 1429
1 Note given true proportions of variables, yes reporting may be common than no reporting
2 May be hospitalised for isolation or medical treatment




3.4.2 Age-sex pyramid



3.4.3 Transmission type

Transmission data were available for 1,660/4,866 (34.1%) of cases.

Note that transmission can occur during sex via skin-to-skin contact as well as via bodily fluids. While skin-to-skin contact with lesions remains an important transmission route, mpox virus has been isolated from semen samples and rectal swabs from confirmed cases. Note that person to person contact does not include known sexual, healthcare-associated, and mother to child transmission.

3.4.4 Exposure settings

Exposure setting data were available for 260/4,866 (5.3%) of cases that were not men who have sex with men.

Note that multiple exposure settings can be attributed to a single case. Here, differentiation between party settings and large events is determined by size of the event, although there is no formal size threshold to distinguish the two.

3.5 Symptomatology

Although most cases in current outbreaks have presented with mild disease symptoms, monkeypox virus (MPXV) may cause severe disease in certain population groups (young children, pregnant women, immunosuppressed persons)

Among the cases who reported at least one symptom, the most common symptom is any rash and is reported in 79% of cases with at least one reported symptom. Note that identifying true denominators for symptomatology is difficult due to a general lack of negative reporting and symptom definitions that may vary between countries’ reporting systems.

A bar chart and table showing symptoms is shown below. Here any rash refers to one or more rash symptoms (systemic, oral, genital, or unknown location), and any lymphadenopathy refers to either general or local lymphadenopathy.

3.5.1 Bar chart - Symptoms

3.5.2 Table - Symptoms

Summary of symptoms
As of January 06 2023
All Male Female
Any rash 29,955 (79.2%) 28,475 (79.7%) 892 (63.2%)
Fever 21,564 (57.0%) 20,520 (57.4%) 685 (48.5%)
Systemic rash 18,884 (49.9%) 17,966 (50.3%) 761 (53.9%)
Genital rash 16,877 (44.6%) 16,111 (45.1%) 332 (23.5%)
Headache 11,876 (31.4%) 11,115 (31.1%) 524 (37.1%)
Any lymphadenopathy 11,085 (29.3%) 10,827 (30.3%) 254 (18.0%)
Muscle ache 9,827 (26.0%) 9,215 (25.8%) 380 (26.9%)
Local lymphadenopathy 7,723 (20.4%) 7,541 (21.1%) 181 (12.8%)
Fatigue 7,390 (19.5%) 6,880 (19.3%) 178 (12.6%)
General lymphadenopathy 7,363 (19.5%) 7,221 (20.2%) 139 (9.9%)
Sore throat 4,964 (13.1%) 4,591 (12.9%) 206 (14.6%)
Rash, unknown location 3,309 (8.7%) 3,286 (9.2%) 20 (1.4%)
Chills 3,152 (8.3%) 2,740 (7.7%) 115 (8.2%)
Oral rash 3,094 (8.2%) 2,597 (7.3%) 70 (5.0%)
Asymptomatic 839 (2.2%) 724 (2.0%) 106 (7.5%)
Other 236 (0.6%) 231 (0.6%) 5 (0.4%)
Conjunctivitis 0 0 0
Cough 0 0 0
Vomiting 0 0 0
Diarrhea 0 0 0
Genital oedema 0 0 0
Lymphadenopathy, location unknown 0 0 0
Anogenital pain and/or bleeding 0 0 0

 


4 Africa in Focus

This section specifically focuses on countries in the African region, in order to highlight any differences in epidemiology between this region and others regarding the ongoing 2022 mpox outbreak. Historically, the sexual component of transmission in the region has been thought to contribute less to human to human transmission of mpox than has been observed in the ongoing global outbreak. It should also be noted that there is limited testing capacity for mpox in much of the region, which has led to underascertainment of mpox cases.

In 2022, as of 09 Jan 2023, there have been 1,200 confirmed cases of mpox reported in the region and 15 deaths. These represent 1% and 20% of global cases and deaths respectively. In addition, 174 (14% of all cases) detailed cases have been reported to WHO.

Of those cases with detailed data:

  • 111 male cases (64.5%) and 61 female cases (35.5%) have been reported

  • The median age is 25 (IQR: 11 - 36).

  • Of the 169 cases where age was available, there were 65 (38.5% of total) cases reported aged 0-17, out of which 21 (12.4% of total) were aged 0-4.

  • There are currently no case based data for which transmission or exposure setting details are available

Regional trends are shown below:

4.1 Epidemic curve by date of notification (cases)

Epidemic curve shown for cases reported up to 09 Jan 2023 to avoid showing incomplete weeks of data.

4.2 Epidemic curve by date of notification (deaths)

Epidemic curve shown for deaths reported up to 09 Jan 2023 to avoid showing incomplete weeks of data.

4.3 Epidemic curve by date of onset

This epidemic curve is shown for those cases with detailed case data, giving date of onset.

4.4 Age-sex pyramid

 


5 Genomic epidemiology

Sequence alignment and visualisation of sequences available on NCBI Genbank is regularly carried out by Nextstrain, using both historical sequences, and sequences associated with the 2022 multi-country mpox outbreak. On 12 August 2022, after reaching consensus among scientists from different fields and from different countries, WHO decided to rename the mpox clades from the Congo Basin clade as Clade one (I) and the West African clade as Clade two (II). Additionally, it was agreed that the Clade II consists of two subclades, Clade IIa and Clade IIb.

The following visualisations are derived from Nextstrain alignments of Genbank data under the mpxv dataset. Further details on methods and interactive visualisation can be seen on the Nextclade website and GitHub. Phylogenetic trees were visualised in R with the ggtree and treeio packages. As of 21 Nov 2022, a total of 586 sequences were visualised. Note that these data do not include data submitted to GISAID, the other major platform for sharing mpox genomic data.

At present, all sequences in the ongoing 2022 mpox outbreak are associated with Clade IIb. Among these, the vast majority have been associated with the B.1 lineage of Clade IIb. Despite this however, a number of sequences have been associated with the related A.2 lineage. Currently, the similarities between the sequences uploaded from different areas of the world suggest that the ongoing outbreak does not involve multiple zoonotic spillover events, and transmission is sustained through human-to-human transmission. In order to understand when sustained human to human transmission has started, it is critical to analyse the diversity of sequences from the period prior to the current outbreak in countries that experienced continuous circulation of mpox.

5.1 Phylogeny focused on 2022 outbreak

Click on image to expand

5.2 Phylogeny prior to 2022 outbreak

Click on image to expand

 

6 Literature Summary & Epidemic Parameters

In order to promote a better understanding of the dynamics of the current mpox outbreak and to support forecasting work, WHO has undertaken an effort to extract epidemiological parameters, such as incubation period and generation interval, from the literature. The initial literature screening is performed and maintained by the Public Health Agency of Canada (PHAC). The overall search strategy is as follows:

  • Inclusion criteria: monkeypox and monkeypox virus
  • Study design:
    • Any study design including primary and secondary studies (both animal and human)
    • Guidelines and commentaries are not excluded but are not searched systematically.
  • Publication language: no restriction for peer-reviewed articles, grey literature is focused on English
  • Publication date: from April 14, 2022
  • Bibliographic databases and other sources searched:
    • PubMed Scopus
    • Pre-print servers: Europe PMC, arXiv and SSRN
    • WHO, PHAC, CDC, ECDC, UKHSA

The tables below provide an overview of the most relevant estimates for incubation period and generation interval extracted from the literature where the following criteria are met:

  • Studies with a sample size greater than 5
  • Clear estimate of the specific parameter

The epidemic parameter tables are updated once per week on Fridays. Please note that some of these sources are still undergoing the peer-review process, therefore readers are advised to exercise care when interpreting findings.

6.1 Parameters

Incubation Period
As of 28 Nov 2022
Reference N Mean1 95% CrI (mean)1 95% CI (mean)1 SD1 Median1 95% CrI (median)1 IQR1 Range1 Distribution
Miura et al. [1] 18 8.5 6.6 - 10.9 - - - - - - Log-normal
Charniga et al. [2] 40 7.6 6.2 - 9.7 - 1.8 6.4 5.1 - 7.9 - - Log-normal
Rodríguez et al. [3] 45 - - - - - - - - -
Thornhill et al. [4] 23 - - - - 7.0 - - 3 - 20 -
Català et al. [5] 77 - - - - 6.0 - - 4 - 9 -
Tarín-Vicente et al. [6] 144 - - - - 7.0 - 5 - 10 1 - 19 -
Guzzetta et al. [7] 30 9.1 - 6.5 - 10.9 - - - - - Gamma
Mailhe et al. [8] 112 - - - - 6.0 - 3 - 8 - -
Moschese et al. [9] 16 - - - - 11.0 - 11 - 16 - -
Gomez-Garberi et al. [10] 14 - - - - 13.0 - - 3 - 30 -
O'Laughlin et al. [11] 527 7.0 - - - - - 4 - 9 - -
Angelo et al. [12] 78 - - - - 8.0 - 5 - 11 2 - 40 -
Madewell et al. [14] 35 5.6 4.3 - 7.8 - - - - - - -
Ward et al. [15] 54 7.8 6.6 - 9.2 - - - - - - Weibull
Besombes et al. [16] 29 - - - - 7.0 - 1 - 13 0 - 17 -
Kröger et al. [17] 209 8.2 - - 4.7 - - - - Log-normal
Source: PHAC
1 Units are in days




Serial Interval
As of 28 Nov 2022
Reference N Mean1 95% CrI (mean)1 Median1 95% CrI (median)1 Distribution
Guo et al. [13] 21 5.6 1.7 - 10.4 5.5 1.4 - 10.4 -
Madewell et al. [14] 57 8.5 7.3 - 9.9 - - Gamma
Ward et al. [15] 79 9.5 7.4 - 12.3 - - Gamma
Source: PHAC
1 Units are in days




Generation Interval
As of 28 Nov 2022
Reference N Mean1 95% CrI1 Distribution
Guzzetta et al. [7] 16 12.5 7.5 - 17.3 Gamma
Source: PHAC
1 Units are in days


6.2 Bibliography

  1. The incubation period for monkeypox cases confirmed in the Netherlands, May 2022 ( 658) medRxiv . Miura, Fuminari, van Ewijk, Catharina Else, Backer, Jantien A., Xiridou, Maria, Franz, Eelco, de Coul, Eline Op, Brandwagt, Diederik, van Cleef, Brigitte, van Rijckevorsel, Gini, Swaan, Corien, van den Hof, Susan, Wallinga, Jacco. #volume# (2022): 2022.06.09.22276068–> 10.1101/2022.06.09.22276068 ; http://medrxiv.org/content/early/2022/06/13/2022.06.09.22276068.abstract

  2. Estimating the incubation period of monkeypox virus during the 2022 multi-national outbreak ( 722) medRxiv . Charniga, Kelly, Masters, Nina B., Slayton, Rachel B., Gosdin, Lucas, Minhaj, Faisal S., Philpott, David, Smith, Dallas, Gearhart, Shannon, Alvarado-Ramy, Francisco, Brown, Clive, Waltenburg, Michelle A., Hughes, Christine M., Nakazawa, Yoshinori. #volume# (2022): 2022.06.22.22276713–> 10.1101/2022.06.22.22276713 ; http://medrxiv.org/content/early/2022/06/23/2022.06.22.22276713.abstract

  3. Epidemiologic Features and Control Measures during Monkeypox Outbreak, Spain, June 2022 ( 888) Emerg Infect Dis . Rodríguez, B. S., Herrador, B. R. G., Franco, A. D., Fariñas, M. P. S., Del Amo Valero, J., Llorente, A. H. A., de Agreda, Jpap, Malonda, R. C., Castrillejo, D., Chirlaque López, M. D., Chong, E. J., Balbuena, S. F., García, V. G., García-Cenoz, M., Hernández, L. G., Montalbán, E. G., Carril, F. G., Cortijo, T. G., Bueno, S. J., Sánchez, A. L., Linares Dópido, J. A., Lorusso, N., Martins, M. M., Martínez Ochoa, E. M., Mateo, A. M., Peña, J. M., Antón, A. I. N., Otero Barrós, M. T., Martinez, Mdcp, Jiménez, P. P., Martín, O. P., Rivas Pérez, A. I., García, M. S., Soria, F. S., Sierra Moros, M. J.. 28,2022/07/13 (2022): #pages#–> 10.3201/eid2809.221051 ; https://wwwnc.cdc.gov/eid/article/28/9/22-1051_article

  4. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 ( 933) N Engl J Med . Thornhill, J. P., Barkati, S., Walmsley, S., Rockstroh, J., Antinori, A., Harrison, L. B., Palich, R., Nori, A., Reeves, I., Habibi, M. S., Apea, V., Boesecke, C., Vandekerckhove, L., Yakubovsky, M., Sendagorta, E., Blanco, J. L., Florence, E., Moschese, D., Maltez, F. M., Goorhuis, A., Pourcher, V., Migaud, P., Noe, S., Pintado, C., Maggi, F., Hansen, A. E., Hoffmann, C., Lezama, J. I., Mussini, C., Cattelan, A., Makofane, K., Tan, D., Nozza, S., Nemeth, J., Klein, M. B., Orkin, C. M.. 2022/07/23 (2022): #pages#–> 10.1056/NEJMoa2207323 ; #URL#

  5. Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases ( 1008) Br J Dermatol . Català, A., Clavo Escribano, P., Riera, J., Martín-Ezquerra, G., Fernandez-Gonzalez, P., Revelles Peñas, L., Simón Gozalbo, A., Rodríguez-Cuadrado, F. J., Guilera Castells, V., De la Torre Gomar, F. J., Comunión Artieda, A., Fuertes de Vega, L., Blanco, J. L., Puig, S., García Miñarro Á, M., Fiz Benito, E., Muñoz-Santos, C., Repiso-Jiménez, J. B., Ceballos-Rodriguez, C., García Rodríguez, V., Castaño Fernández, J. L., Sánchez-Gutiérrez, I., Calvo López, R., Berna-Rico, E., de Nicolás-Ruanes, B., Corella Vicente, F., Tarín Vicente, E. J., Fernández de la Fuente, L., Riera-Martí, N., Descalzo-Gallego, M., Grau-Perez, M., García-Doval, I., Fuertes, I.. 2022/08/03 (2022): #pages#–> 10.1111/bjd.21790 ; #URL#

  6. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study ( 1074) Lancet . Tarín-Vicente, E. J., Alemany, A., Agud-Dios, M., Ubals, M., Suñer, C., Antón, A., Arando, M., Arroyo-Andrés, J., Calderón-Lozano, L., Casañ, C., Cabrera, J. M., Coll, P., Descalzo, V., Folgueira, M. D., García-Pérez, J. N., Gil-Cruz, E., González-Rodríguez, B., Gutiérrez-Collar, C., Hernández-Rodríguez, Á., López-Roa, P., de Los Ángeles Meléndez, M., Montero-Menárguez, J., Muñoz-Gallego, I., Palencia-Pérez, S. I., Paredes, R., Pérez-Rivilla, A., Piñana, M., Prat, N., Ramirez, A., Rivero, Á., Rubio-Muñiz, C. A., Vall, M., Acosta-Velásquez, K. S., Wang, A., Galván-Casas, C., Marks, M., Ortiz-Romero, P., Mitjà, O.. 2022/08/12 (2022): #pages#–> 10.1016/s0140-6736(22)01436-2 ; #URL#

  7. Early Estimates of Monkeypox Incubation Period, Generation Time, and Reproduction Number, Italy, May-June 2022 ( 1189) Emerg Infect Dis . Guzzetta, G., Mammone, A., Ferraro, F., Caraglia, A., Rapiti, A., Marziano, V., Poletti, P., Cereda, D., Vairo, F., Mattei, G., Maraglino, F., Rezza, G., Merler, S.. 28,2022/08/23 (2022): #pages#–> 10.3201/eid2810.221126 ; https://wwwnc.cdc.gov/eid/article/28/10/22-1126_article

  8. Clinical characteristics of ambulatory and hospitalised patients with monkeypox virus infection: an observational cohort study ( 1238) Clin Microbiol Infect . Mailhe, M., Beaumont, A. L., Thy, M., Le Pluart, D., Perrineau, S., Houhou-Fidouh, N., Deconinck, L., Bertin, C., Ferré, V. M., Cortier, M., C.,De La Porte Des Vaux,, Phung, B. C., Mollo, B., Cresta, M., Bouscarat, F., Choquet, C., Descamps, D., Ghosn, J., Lescure, F. X., Yazdanpanah, Y., Joly, V., Peiffer-Smadja, N.. 2022/08/27 (2022): #pages#–> 10.1016/j.cmi.2022.08.012 ; #URL#

  9. Natural history of Human Monkeypox in individuals attending a sexual health clinic in Milan, Italy ( 1262) J Infect . Moschese, D., Pozza, G., Giacomelli, A., Mileto, D., Cossu, M. V., Beltrami, M., Rizzo, A., Gismondo, M. R., Rizzardini, G., Antinori, S.. 2022/08/26 (2022): #pages#–> 10.1016/j.jinf.2022.08.019 ; #URL#

  10. Genitourinary Lesions Due to Monkeypox ( 1440) Eur Urol . Gomez-Garberi, M., Sarrio-Sanz, P., Martinez-Cayuelas, L., Delgado-Sanchez, E., Bernabeu-Cabezas, S., Peris-Garcia, J., Sanchez-Caballero, L., Nakdali-Kassab, B., Egea-Sancho, C., Olarte-Barragan, E., Ortiz-Gorraiz, M.. 2022/09/13 (2022): #pages#–> 10.1016/j.eururo.2022.08.034 ; #URL#

  11. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022 ( 1486) MMWR Morb Mortal Wkly Rep . O’Laughlin, K., Tobolowsky, F. A., Elmor, R., Overton, R., O’Connor, S. M., Damon, I. K., Petersen, B. W., Rao, A. K., Chatham-Stephens, K., Yu, P., Yu, Y.. 71,2022/09/16 (2022): 1190–> 10.15585/mmwr.mm7137e1 ; #URL#

  12. Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study ( 1748) Lancet Infect Dis . Angelo, K. M., Smith, T., Camprubí-Ferrer, D., Balerdi-Sarasola, L., Díaz Menéndez, M., Servera-Negre, G., Barkati, S., Duvignaud, A., Huber, K. L. B., Chakravarti, A., Bottieau, E., Greenaway, C., Grobusch, M. P., Mendes Pedro, D., Asgeirsson, H., Popescu, C. P., Martin, C., Licitra, C., de Frey, A., Schwartz, E., Beadsworth, M., Lloveras, S., Larsen, C. S., Guagliardo, S. A. J., Whitehill, F., Huits, R., Hamer, D. H., Kozarsky, P., Libman, M.. 2022/10/11 (2022): #pages#–> 10.1016/s1473-3099(22)00651-x ; #URL#

  13. Estimation of the serial interval of monkeypox during the early outbreak in 2022 ( 1895) J Med Virol . Guo, Z., Zhao, S., Sun, S., He, D., Chong, K. C., Yeoh, E. K.. 2022/10/23 (2022): #pages#–> 10.1002/jmv.28248 ; #URL#

  14. Serial interval and incubation period estimates of monkeypox virus infection in 12 U.S. jurisdictions, May - August 2022 ( 2007) medRxiv . Madewell, Zachary, Charniga, Kelly, Masters, Nina, Asher, Jason, Fahrenwald, Lily, Still, William, Chen, Judy, Kipperman, Naama, Bui, David, Shea, Meghan, Saathoff-Huber, Lori, Johnson, Shannon, Harbi, Khalil, Berns, Abby, Perez, Taidy, Gateley, Emily, Spicknall, Ian, Nakazawa, Yoshinori, Gift, Thomas. #volume# (2022): #pages#–> 10.1101/2022.10.26.22281516 ; http://europepmc.org/abstract/PPR/PPR564657 https://doi.org/10.1101/2022.10.26.22281516

  15. Transmission dynamics of monkeypox in the United Kingdom: contact tracing study ( 2069) Bmj . Ward, T., Christie, R., Paton, R. S., Cumming, F., Overton, C. E.. 379,2022/11/03 (2022): e073153–> 10.1136/bmj-2022-073153 ; #URL#

  16. National Monkeypox Surveillance, Central African Republic, 2001-2021 ( 2104) Emerg Infect Dis . Besombes, C., Mbrenga, F., Schaeffer, L., Malaka, C., Gonofio, E., Landier, J., Vickos, U., Konamna, X., Selekon, B., Dankpea, J. N., Von Platen, C., Houndjahoue, F. G., Ouaïmon, D. S., Hassanin, A., Berthet, N., Manuguerra, J. C., Gessain, A., Fontanet, A., Yandoko, E. N.. 28,2022/11/04 (2022): #pages#–> 10.3201/eid2812.220897 ; https://wwwnc.cdc.gov/eid/article/28/12/22-0897_article

  17. Monkeypox outbreak 2022 – an overview of all cases reported to the Cologne Health Department ( 2181) Research Square . Kröger, Sophia Toya, Lehmann, Max Christian, Treutlein, Melanie, Fiethe, Achim, Kossow, Annelene, Küfer-Weiß, Annika, Nießen, Johannes, Grüne, Barbara. #volume# (2022): #pages#–> 10.21203/rs.3.rs-2251751/v1 ; http://europepmc.org/abstract/PPR/PPR570380 https://doi.org/10.21203/rs.3.rs-2251751/v1

 


7 Disclaimers

7.1 Data Overview and Visualizations

The WHO 2022 mpox global trends report aims to provide frequently updated data visualizations. Caution must be taken when interpreting all data presented, and differences between information products published by WHO, national public health authorities, and other sources using different inclusion criteria and different data cut-off times are to be expected. While steps are taken to ensure accuracy and reliability, all data are subject to continuous verification and change. All counts are subject to variations in case detection, definitions, laboratory testing, and reporting strategies between countries, states and territories.

WHO makes no warranties or representations regarding the contents, appearance, completeness, technical specifications, or accuracy of the report. WHO disclaims all responsibility relating to, and shall not be liable for, any use of the report, the results of such use, or the reliance thereon.

WHO reserves the right to make updates and changes to the report without notice, and accepts no liability for any errors or omissions in this regard.

The user of the report is responsible for the interpretation and use of the analysis and outputs performed by the report. The submission of content to the report does not imply WHO’s approval or endorsement of that content, or that the content is appropriate for any purpose or meets any established standard or requirement

Any designations employed or presentation by the user in its use of the app, including tables and maps, do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries.

All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).

8 Acknowledgements

We gratefully acknowledge the input of national public health staff involved in surveillance activities and data submission to WHO, the European Centre for Disease Prevention and Control (ECDC) for the provision of surveillance data collected via the TESSy platform, as well as external partners who contributed additional insights and contextual information on the data.